 |
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Immune system
|
PDB id
|
|
|
|
1ljt
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Immune system
|
 |
|
Title:
|
 |
Crystal structure of macrophage migration inhibitory factor complexed with (s,r)-3-(4-hydroxyphenyl)-4,5-dihydro-5- isoxazole-acetic acid methyl ester (iso-1)
|
|
Structure:
|
 |
Macrophage migration inhibitory factor. Chain: a, b, c. Engineered: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Expressed in: escherichia coli bl21(de3). Expression_system_taxid: 469008.
|
|
Biol. unit:
|
 |
Trimer (from
)
|
|
Resolution:
|
 |
|
2.00Å
|
R-factor:
|
0.237
|
R-free:
|
0.262
|
|
|
Authors:
|
 |
J.B.Lubetsky,A.Dios,J.Han,B.Aljabari,B.Ruzsicska,R.Mitchell, E.Lolis,Y.Al-Abed
|
Key ref:
|
 |
J.B.Lubetsky
et al.
(2002).
The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents.
J Biol Chem,
277,
24976-24982.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
22-Apr-02
|
Release date:
|
27-Nov-02
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
|
|
|
P14174
(MIF_HUMAN) -
Macrophage migration inhibitory factor
|
|
|
|
Seq: Struc:
|
 |
 |
 |
115 a.a.
114 a.a.
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class 2:
|
 |
E.C.5.3.2.1
- Phenylpyruvate tautomerase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Keto-phenylpyruvate = enol-phenylpyruvate
|
 |
 |
 |
 |
 |
Keto-phenylpyruvate
Bound ligand (Het Group name = )
matches with 61.00% similarity
|
=
|
enol-phenylpyruvate
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 3:
|
 |
E.C.5.3.3.12
- L-dopachrome isomerase.
|
|
 |
 |
 |
 |
 |

Pathway:
|
 |
|
 |
 |
 |
 |
 |
Reaction:
|
 |
L-dopachrome = 5,6-dihydroxyindole-2-carboxylate
|
 |
 |
 |
 |
 |
L-dopachrome
Bound ligand (Het Group name = )
matches with 55.00% similarity
|
=
|
5,6-dihydroxyindole-2-carboxylate
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Cofactor:
|
 |
Zinc
|
 |
 |
 |
 |
 |
 |
 |
|
Note, where more than one E.C. class is given (as above), each may
correspond to a different protein domain or, in the case of polyprotein
precursors, to a different mature protein.
|
|
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Cellular component
|
extracellular region
|
4 terms
|
 |
|
Biological process
|
cell proliferation
|
31 terms
|
 |
|
Biochemical function
|
chemoattractant activity
|
9 terms
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
J Biol Chem
277:24976-24982
(2002)
|
|
PubMed id:
|
|
|
|
|
| |
|
The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents.
|
|
J.B.Lubetsky,
A.Dios,
J.Han,
B.Aljabari,
B.Ruzsicska,
R.Mitchell,
E.Lolis,
Y.Al-Abed.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Macrophage migration inhibitory factor (MIF) is an immunoregulatory protein that
is a potential therapeutic target for a number of inflammatory diseases.
Evidence exists that an unexpected catalytic active site of MIF may have a
biological function. To gain further insight into the role of the catalytic
active site, a series of mutational, structural, and biological activity studies
were performed. The insertion of an alanine between Pro-1 and Met-2 (PAM)
abolishes a non-physiological catalytic activity, and this mutant is defective
in the in vitro glucocorticoid counter-regulatory activity of MIF. The crystal
structure of MIF complexed to (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole
acetic acid methyl ester (ISO-1), an inhibitor of MIF d-dopachrome tautomerase
activity, reveals that ISO-1 binds to the same position of the active site as
p-hydroxyphenylpyruvic acid, a substrate of MIF. ISO-1 inhibits several MIF
biological activities, further establishing a role for the catalytic active site
of MIF.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 6.
Fig. 6. Superposition of uncomplexed MIF and
MIF·ISO-1. Backbone atom traces are shown for the trimer
arrangements of uncomplexed MIF (black) and MIF·ISO-1
(gray). All atoms from the active site residues (Pro-1, Lys-32,
Ile-64, Tyr-95, and Asn-97) are also displayed. This
superposition reveals that there are no major conformational
changes upon inhibitor binding. This figure was prepared with
the program INSIGHTII (Molecular Simulations, Inc.).
|
 |
Figure 7.
Fig. 7. Structure of ISO-1 and MIF. A, 2F[o] F[c] omit
map at 1 for ISO-1
in the catalytic active site of MIF. The R-isomer is modeled in
the electron density. The catalytic active site residues are
displayed. B, schematic of the interactions between protein
residues of MIF and ISO-1. All distances, with the exception of
Pro-1A, represent hydrogen bonds. A series of aromatic-aromatic
interactions, hydrogen bonds, and van der Waals contacts provide
the binding energy for ISO-1. Pro-1A, Lys-32A, and Ile-64A are
from one subunit, and Tyr-95C and Asn-97C are from an adjacent
subunit. This figure was prepared with Bobscript (52) and
ChemDraw (CambridgeSoft Corp., Cambridge, MA).
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from the ASBMB:
J Biol Chem
(2002,
277,
24976-24982)
copyright 2002.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
A.R.Inácio,
K.Ruscher,
L.Leng,
R.Bucala,
and
T.Deierborg
(2011).
Macrophage migration inhibitory factor promotes cell death and aggravates neurologic deficits after experimental stroke.
|
| |
J Cereb Blood Flow Metab, 31,
1093-1106.
|
 |
|
|
|
|
 |
N.Baron,
O.Deuster,
C.Noelker,
C.Stüer,
H.Strik,
C.Schaller,
R.Dodel,
B.Meyer,
and
M.Bacher
(2011).
Role of macrophage migration inhibitory factor in primary glioblastoma multiforme cells.
|
| |
J Neurosci Res, 89,
711-717.
|
 |
|
|
|
|
 |
A.Baeza Garcia,
R.J.Pierce,
B.Gourbal,
E.Werkmeister,
D.Colinet,
J.M.Reichhart,
C.Dissous,
and
C.Coustau
(2010).
Involvement of the cytokine MIF in the snail host immune response to the parasite Schistosoma mansoni.
|
| |
PLoS Pathog, 6,
0.
|
 |
|
|
|
|
 |
C.C.Chuang,
Y.C.Chuang,
W.T.Chang,
C.C.Chen,
L.I.Hor,
A.M.Huang,
P.C.Choi,
C.Y.Wang,
P.C.Tseng,
and
C.F.Lin
(2010).
Macrophage migration inhibitory factor regulates interleukin-6 production by facilitating nuclear factor-kappa B activation during Vibrio vulnificus infection.
|
| |
BMC Immunol, 11,
50.
|
 |
|
|
|
|
 |
H.Kimura,
Y.Sato,
Y.Tajima,
H.Suzuki,
H.Yukitake,
T.Imaeda,
M.Kajino,
H.Oki,
M.Takizawa,
and
S.Tanida
(2010).
BTZO-1, a cardioprotective agent, reveals that macrophage migration inhibitory factor regulates ARE-mediated gene expression.
|
| |
Chem Biol, 17,
1282-1294.
|
 |
|
|
|
|
 |
J.L.Liang,
D.Z.Xiao,
X.Y.Liu,
Q.X.Lin,
Z.X.Shan,
J.N.Zhu,
S.G.Lin,
and
X.Y.Yu
(2010).
High glucose induces apoptosis in AC16 human cardiomyocytes via macrophage migration inhibitory factor and c-Jun N-terminal kinase.
|
| |
Clin Exp Pharmacol Physiol, 37,
969-973.
|
 |
|
|
|
|
 |
J.Reimann,
S.Schnell,
S.Schwartz,
K.Kappes-Horn,
R.Dodel,
and
M.Bacher
(2010).
Macrophage migration inhibitory factor in normal human skeletal muscle and inflammatory myopathies.
|
| |
J Neuropathol Exp Neurol, 69,
654-662.
|
 |
|
|
|
|
 |
M.Bacher,
O.Deuster,
B.Aljabari,
R.Egensperger,
F.Neff,
F.Jessen,
J.Popp,
C.Noelker,
J.P.Reese,
Y.Al-Abed,
and
R.Dodel
(2010).
The role of macrophage migration inhibitory factor in Alzheimer's disease.
|
| |
Mol Med, 16,
116-121.
|
 |
|
|
|
|
 |
P.L.Vera,
K.A.Iczkowski,
D.J.Howard,
L.Jiang,
and
K.L.Meyer-Siegler
(2010).
Antagonism of macrophage migration inhibitory factor decreases cyclophosphamide cystitis in mice.
|
| |
Neurourol Urodyn, 29,
1451-1457.
|
 |
|
|
|
|
 |
Y.Cho,
G.V.Crichlow,
J.J.Vermeire,
L.Leng,
X.Du,
M.E.Hodsdon,
R.Bucala,
M.Cappello,
M.Gross,
F.Gaeta,
K.Johnson,
and
E.J.Lolis
(2010).
Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast.
|
| |
Proc Natl Acad Sci U S A, 107,
11313-11318.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
B.E.Rendon,
S.S.Willer,
W.Zundel,
and
R.A.Mitchell
(2009).
Mechanisms of macrophage migration inhibitory factor (MIF)-dependent tumor microenvironmental adaptation.
|
| |
Exp Mol Pathol, 86,
180-185.
|
 |
|
|
|
|
 |
B.L.Barrilleaux,
D.G.Phinney,
B.W.Fischer-Valuck,
K.C.Russell,
G.Wang,
D.J.Prockop,
and
K.C.O'Connor
(2009).
Small-molecule antagonist of macrophage migration inhibitory factor enhances migratory response of mesenchymal stem cells to bronchial epithelial cells.
|
| |
Tissue Eng Part A, 15,
2335-2346.
|
 |
|
|
|
|
 |
C.Piette,
M.Deprez,
T.Roger,
A.Noël,
J.M.Foidart,
and
C.Munaut
(2009).
The dexamethasone-induced inhibition of proliferation, migration, and invasion in glioma cell lines is antagonized by macrophage migration inhibitory factor (MIF) and can be enhanced by specific MIF inhibitors.
|
| |
J Biol Chem, 284,
32483-32492.
|
 |
|
|
|
|
 |
G.V.Crichlow,
J.B.Lubetsky,
L.Leng,
R.Bucala,
and
E.J.Lolis
(2009).
Structural and kinetic analyses of macrophage migration inhibitory factor active site interactions.
|
| |
Biochemistry, 48,
132-139.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
J.Schrader,
O.Deuster,
B.Rinn,
M.Schulz,
A.Kautz,
R.Dodel,
B.Meyer,
Y.Al-Abed,
K.Balakrishnan,
J.P.Reese,
and
M.Bacher
(2009).
Restoration of contact inhibition in human glioblastoma cell lines after MIF knockdown.
|
| |
BMC Cancer, 9,
464.
|
 |
|
|
|
|
 |
K.Takahashi,
K.Koga,
H.M.Linge,
Y.Zhang,
X.Lin,
C.N.Metz,
Y.Al-Abed,
K.Ojamaa,
and
E.J.Miller
(2009).
Macrophage CD74 contributes to MIF-induced pulmonary inflammation.
|
| |
Respir Res, 10,
33.
|
 |
|
|
|
|
 |
S.E.Dobson,
K.D.Augustijn,
J.A.Brannigan,
C.Schnick,
C.J.Janse,
E.J.Dodson,
A.P.Waters,
and
A.J.Wilkinson
(2009).
The crystal structures of macrophage migration inhibitory factor from Plasmodium falciparum and Plasmodium berghei.
|
| |
Protein Sci, 18,
2578-2591.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
X.X.He,
K.Chen,
J.Yang,
X.Y.Li,
H.Y.Gan,
C.Y.Liu,
T.R.Coleman,
and
Y.Al-Abed
(2009).
Macrophage migration inhibitory factor promotes colorectal cancer.
|
| |
Mol Med, 15,
1.
|
 |
|
|
|
|
 |
Z.Cournia,
L.Leng,
S.Gandavadi,
X.Du,
R.Bucala,
and
W.L.Jorgensen
(2009).
Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening.
|
| |
J Med Chem, 52,
416-424.
|
 |
|
|
|
|
 |
A.Kudrin,
and
D.Ray
(2008).
Cunning factor: macrophage migration inhibitory factor as a redox-regulated target.
|
| |
Immunol Cell Biol, 86,
232-238.
|
 |
|
|
|
|
 |
D.Kamir,
S.Zierow,
L.Leng,
Y.Cho,
Y.Diaz,
J.Griffith,
C.McDonald,
M.Merk,
R.A.Mitchell,
J.Trent,
Y.Chen,
Y.K.Kwong,
H.Xiong,
J.Vermeire,
M.Cappello,
D.McMahon-Pratt,
J.Walker,
J.Bernhagen,
E.Lolis,
and
R.Bucala
(2008).
A Leishmania ortholog of macrophage migration inhibitory factor modulates host macrophage responses.
|
| |
J Immunol, 180,
8250-8261.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
D.Rittirsch,
M.A.Flierl,
and
P.A.Ward
(2008).
Harmful molecular mechanisms in sepsis.
|
| |
Nat Rev Immunol, 8,
776-787.
|
 |
|
|
|
|
 |
M.Winner,
J.Meier,
S.Zierow,
B.E.Rendon,
G.V.Crichlow,
R.Riggs,
R.Bucala,
L.Leng,
N.Smith,
E.Lolis,
J.O.Trent,
and
R.A.Mitchell
(2008).
A novel, macrophage migration inhibitory factor suicide substrate inhibits motility and growth of lung cancer cells.
|
| |
Cancer Res, 68,
7253-7257.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
P.W.West,
L.C.Parker,
J.R.Ward,
and
I.Sabroe
(2008).
Differential and cell-type specific regulation of responses to Toll-like receptor agonists by ISO-1.
|
| |
Immunology, 125,
101-110.
|
 |
|
|
|
|
 |
W.R.Parrish,
M.Gallowitsch-Puerta,
C.J.Czura,
and
K.J.Tracey
(2008).
Experimental therapeutic strategies for severe sepsis: mediators and mechanisms.
|
| |
Ann N Y Acad Sci, 1144,
210-236.
|
 |
|
|
|
|
 |
A.Arjona,
H.G.Foellmer,
T.Town,
L.Leng,
C.McDonald,
T.Wang,
S.J.Wong,
R.R.Montgomery,
E.Fikrig,
and
R.Bucala
(2007).
Abrogation of macrophage migration inhibitory factor decreases West Nile virus lethality by limiting viral neuroinvasion.
|
| |
J Clin Invest, 117,
3059-3066.
|
 |
|
|
|
|
 |
B.Aljabari,
A.E.Calogero,
A.Perdichizzi,
E.Vicari,
R.Karaki,
T.Lahloub,
R.Zatari,
K.El-Abed,
F.Nicoletti,
E.J.Miller,
V.A.Pavlov,
and
Y.Al-Abed
(2007).
Imbalance in seminal fluid MIF indicates male infertility.
|
| |
Mol Med, 13,
199-202.
|
 |
|
|
|
|
 |
G.J.Poelarends,
W.H.Johnson,
H.Serrano,
and
C.P.Whitman
(2007).
Phenylpyruvate tautomerase activity of trans-3-chloroacrylic acid dehalogenase: evidence for an enol intermediate in the dehalogenase reaction?
|
| |
Biochemistry, 46,
9596-9604.
|
 |
|
|
|
|
 |
M.Winner,
A.C.Koong,
B.E.Rendon,
W.Zundel,
and
R.A.Mitchell
(2007).
Amplification of tumor hypoxic responses by macrophage migration inhibitory factor-dependent hypoxia-inducible factor stabilization.
|
| |
Cancer Res, 67,
186-193.
|
 |
|
|
|
|
 |
T.Sakuragi,
X.Lin,
C.N.Metz,
K.Ojamaa,
N.Kohn,
Y.Al-Abed,
and
E.J.Miller
(2007).
Lung-derived macrophage migration inhibitory factor in sepsis induces cardio-circulatory depression.
|
| |
Surg Infect (Larchmt), 8,
29-40.
|
 |
|
|
|
|
 |
E.F.Morand,
M.Leech,
and
J.Bernhagen
(2006).
MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis.
|
| |
Nat Rev Drug Discov, 5,
399-410.
|
 |
|
|
|
|
 |
O.A.Cherepkova,
E.M.Lyutova,
and
B.Y.Gurvits
(2006).
Macrophage migration inhibitory factor: isolation from bovine brain.
|
| |
Biochemistry (Mosc), 71,
73-78.
|
 |
|
|
|
|
 |
J.M.Wilson,
P.L.Coletta,
R.J.Cuthbert,
N.Scott,
K.MacLennan,
G.Hawcroft,
L.Leng,
J.B.Lubetsky,
K.K.Jin,
E.Lolis,
F.Medina,
J.A.Brieva,
R.Poulsom,
A.F.Markham,
R.Bucala,
and
M.A.Hull
(2005).
Macrophage migration inhibitory factor promotes intestinal tumorigenesis.
|
| |
Gastroenterology, 129,
1485-1503.
|
 |
|
|
|
|
 |
O.A.Cherepkova,
E.M.Lutova,
and
B.Y.Gurvits
(2005).
Charge heterogeneity of bovine brain macrophage migration inhibitory factor.
|
| |
Neurochem Res, 30,
151-158.
|
 |
|
|
|
|
 |
R.Wadgaonkar,
S.M.Dudek,
A.L.Zaiman,
L.Linz-McGillem,
A.D.Verin,
S.Nurmukhambetova,
L.H.Romer,
and
J.G.Garcia
(2005).
Intracellular interaction of myosin light chain kinase with macrophage migration inhibition factor (MIF) in endothelium.
|
| |
J Cell Biochem, 95,
849-858.
|
 |
|
|
|
|
 |
E.Lolis,
and
R.Bucala
(2003).
Therapeutic approaches to innate immunity: severe sepsis and septic shock.
|
| |
Nat Rev Drug Discov, 2,
635-645.
|
 |
|
|
|
|
 |
E.Lolis,
and
R.Bucala
(2003).
Macrophage migration inhibitory factor.
|
| |
Expert Opin Ther Targets, 7,
153-164.
|
 |
|
|
|
|
 |
T.Calandra,
C.Froidevaux,
C.Martin,
and
T.Roger
(2003).
Macrophage migration inhibitory factor and host innate immune defenses against bacterial sepsis.
|
| |
J Infect Dis, 187,
S385-S390.
|
 |
|
|
|
|
 |
T.Calandra,
and
T.Roger
(2003).
Macrophage migration inhibitory factor: a regulator of innate immunity.
|
| |
Nat Rev Immunol, 3,
791-800.
|
 |
|
|
|
|
 |
U.Arndt,
G.Wennemuth,
P.Barth,
M.Nain,
Y.Al-Abed,
A.Meinhardt,
D.Gemsa,
and
M.Bacher
(2002).
Release of macrophage migration inhibitory factor and CXCL8/interleukin-8 from lung epithelial cells rendered necrotic by influenza A virus infection.
|
| |
J Virol, 76,
9298-9306.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
|